NextCure, Inc. - Common Stock (NXTC)
Frequently Asked Questions About NextCure, Inc. - Common Stock (NXTC)
How does NextCure approach drug development?
NextCure employs a rigorous drug development process that encompasses preclinical research, clinical trials, and regulatory approvals. The company emphasizes early-stage research to identify promising therapeutic targets followed by iterative clinical trials designed to evaluate safety and efficacy.
How does NextCure contribute to advancements in cancer treatment?
NextCure contributes to advancements in cancer treatment by pioneering novel immunotherapeutic approaches, conducting cutting-edge research, and developing therapies that enhance immune system function. The company aims to address unmet medical needs in oncology, leveraging scientific advancements to improve treatment outcomes for patients.
How does NextCure engage with the investor community?
NextCure engages with the investor community through regular financial updates, investor presentations, and participation in investor conferences. The company aims to maintain transparency and keep stakeholders informed about its progress and strategic initiatives.
How does NextCure ensure the quality of its products?
NextCure ensures the quality of its products through stringent quality control processes and adherence to Good Manufacturing Practices (GMP). The company maintains oversight throughout the product development lifecycle, from research and development to clinical trials and commercialization.
Is NextCure a publicly traded company?
Yes, NextCure, Inc. is publicly traded on the Nasdaq stock exchange under the ticker symbol NXTC. The company went public in 2019, providing it with capital to further its research, development, and commercialization efforts.
What are some of NextCure's key product candidates?
NextCure's key product candidates include NC318, an investigational therapy targeting specific immune checkpoints to enhance anti-tumor immunity, and NC410, a therapy designed to activate T cells. These candidates are in various stages of clinical development and are being evaluated for their efficacy in treating different cancers.
What are the company’s long-term goals?
NextCure's long-term goals include advancing its pipeline of immuno-oncology therapies through successful clinical trials, achieving regulatory approvals, and ultimately delivering innovative treatments to patients. The company's vision also focuses on expanding its research capabilities and broadening its therapeutic focus to address additional diseases.
What clinical trials is NextCure currently conducting?
NextCure is currently conducting several clinical trials to evaluate its lead candidates NC318 and NC410. These trials are designed to assess both efficacy and safety profiles of the therapies in various cancer patient populations, providing essential data for future regulatory submissions.
What competitive landscape does NextCure operate in?
NextCure operates within a highly competitive landscape of biotechnology and pharmaceutical companies focused on immunotherapy and oncology. The competition includes established firms and emerging companies, all aiming to develop effective therapies for cancer treatment, making the market dynamic and challenging.
What does NextCure, Inc. do?
NextCure, Inc. is a biotechnology company focused on developing innovative immunotherapies to treat cancer and other immune-related diseases. The company aims to harness the power of the immune system to recognize and combat tumors using its proprietary technology platforms, including its product candidates that are designed to target specific immune checkpoints.
What is the company's mission?
NextCure's mission is to improve the lives of patients suffering from cancer and other disease conditions by discovering and developing next-generation immunotherapies. The company is committed to utilizing innovative approaches to unlock the immune system's potential to combat malignancies effectively.
What makes NextCure unique in the biopharmaceutical space?
NextCure is unique due to its targeted approach in the immunotherapy field and its focus on leveraging proprietary technologies that identify immune dysfunctions in tumors. This allows the company to develop therapies that offer new mechanisms of action, differentiating it from other biopharmaceutical firms.
What partnerships or collaborations has NextCure formed?
NextCure has established various partnerships with academic institutions, research organizations, and other biotech companies to enhance its research capabilities and accelerate the development of its product candidates. These collaborations are crucial for sharing knowledge and resources to tackle complex challenges in cancer treatment.
What regulatory approvals does NextCure seek?
NextCure seeks regulatory approval from entities such as the U.S. Food and Drug Administration (FDA) for its investigational products. This includes submitting New Drug Applications (NDAs) and Biologics License Applications (BLAs) once clinical trials demonstrate safety and efficacy.
What therapeutic areas does NextCure focus on?
NextCure primarily focuses on oncology and immune-related diseases. By targeting various forms of cancer, the company seeks to innovate treatment protocols and offer new hope to patients suffering from malignancies that are currently difficult to treat.
What were NextCure's financials in the last reported quarter?
In the most recent quarter reported, NextCure posted financial results highlighting its cash position, research expenditures, and any generated revenues. This financial summary is essential for investors to assess the company's current market standing and future financial health.
When was NextCure founded?
NextCure was founded in 2015 by Dr. John E. McCarthy and Dr. Harlan R. Waksal. The company was established with the goal of advancing novel immunotherapeutics that leverage the body’s immune response to fight various types of cancer and improve patient outcomes.
Where is NextCure headquartered?
NextCure is headquartered in Beltsville, Maryland. The location was chosen to provide access to a rich ecosystem of research institutions, talent, and resources available in the greater Washington, D.C. metropolitan area.
Who are the key executives at NextCure?
Key executives at NextCure include CEO Dr. Michael Richman, who has extensive experience in biotechnology, and other seasoned professionals in research, clinical development, and corporate operations. Their combined expertise drives the company’s strategic vision and operational excellence.
What is the current price of NextCure, Inc. - Common Stock?
The current price of NextCure, Inc. - Common Stock is 0.4358
When was NextCure, Inc. - Common Stock last traded?
The last trade of NextCure, Inc. - Common Stock was at 1:00 pm EDT on July 3rd, 2025
What is the market capitalization of NextCure, Inc. - Common Stock?
The market capitalization of NextCure, Inc. - Common Stock is 12.21M
How many shares of NextCure, Inc. - Common Stock are outstanding?
NextCure, Inc. - Common Stock has 28.01M shares outstanding.